CSF3 and leukemia: The CAG regimen, which combines Aclarubicin with low-dose cytarabine (Ara-C) and G-CSF, is designed to sensitize leukemia cells by using G-CSF to drive them into the cell cycle, thereby enhancing their susceptibility to the cytotoxic drugs.